Starpharma Holdings Limited (SPHRF)
OTHER OTC:SPHRF
Want to see SPHRF full AI Analyst Report?
SPHRF Stock Chart & Stats
$0.21
>-$0.01(-3.96%)
At close: 4:00 PM EST
$0.21
>-$0.01(-3.96%)
Day’s Range― - ―
52-Week Range$0.06 - $0.58
Previous CloseN/A
Volume1.00K
Average Volume (3M)3.00
Market Cap
$182.87M
Enterprise Value$243.52M
Total Cash (Recent Filing)$18.25M
Total Debt (Recent Filing)$790.00K
Price to Earnings (P/E)27.6
Beta0.35
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding420,928,440
10 Day Avg. Volume10
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)1.93
Price to Sales (P/S)7.47
P/FCF Ratio-5.40
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue17.08
Enterprise Value/Gross Profit28.42
Enterprise Value/Ebitda-30.43
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Dendrimer PlatformStarpharma’s proprietary dendrimer technology is a durable competitive asset that supports multiple use cases (drug delivery, anti-infective, topical). A platform model fosters licensing, partnership and product revenue streams that can compound over 2–6 months as programs mature.
Positive Revenue TrendReported revenue growth of ~18% indicates ongoing commercial traction and adoption of products or collaborations. Sustained top-line growth helps justify continued R&D investment, supports milestone and royalty potential, and strengthens negotiation leverage with partners.
Conservative LeverageLow debt and a healthy equity ratio provide financial flexibility to fund R&D or commercialization without immediate refinancing pressure. Conservative leverage reduces solvency risk and preserves strategic optionality for partnerships or selective investments over the medium term.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow indicate the company is burning cash to fund operations and development. This constrains its ability to self-fund programs, raises reliance on external capital, and can dilute shareholders or slow execution if financing conditions tighten.
Ongoing UnprofitabilitySustained negative EBIT and net margins, together with a negative ROE, show the business is not yet converting revenue into returns. This undermines long-term shareholder value creation until margins improve or higher-margin licensing/royalty streams scale.
Limited Scale / Small TeamA modest headcount (~40 employees) may limit capacity to execute simultaneous clinical, regulatory, and commercial initiatives. Limited internal scale increases dependence on partners and contractors, potentially slowing program timelines and commercialization speed.
Starpharma Holdings Limited News
SPHRF FAQ
What was Starpharma Holdings Limited’s price range in the past 12 months?
Starpharma Holdings Limited lowest stock price was $0.06 and its highest was $0.58 in the past 12 months.
What is Starpharma Holdings Limited’s market cap?
Starpharma Holdings Limited’s market cap is $182.87M.
When is Starpharma Holdings Limited’s upcoming earnings report date?
Starpharma Holdings Limited’s upcoming earnings report date is Aug 26, 2026 which is in 97 days.
How were Starpharma Holdings Limited’s earnings last quarter?
Starpharma Holdings Limited released its earnings results on Feb 17, 2026. The company reported $0.002 earnings per share for the quarter, beating the consensus estimate of N/A by $0.002.
Is Starpharma Holdings Limited overvalued?
According to Wall Street analysts Starpharma Holdings Limited’s price is currently Overvalued.
Does Starpharma Holdings Limited pay dividends?
Starpharma Holdings Limited does not currently pay dividends.
What is Starpharma Holdings Limited’s EPS estimate?
Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Starpharma Holdings Limited have?
Starpharma Holdings Limited has 420,928,440 shares outstanding.
What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
Starpharma Holdings Limited reported an EPS of $0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Starpharma Holdings Limited?
Currently, no hedge funds are holding shares in SPHRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Starpharma Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
355.55%
12-Months-Change
Fundamentals
Return on Equity
-15.96%
Trailing 12-Months
Asset Growth
-4.84%
Trailing 12-Months
Company Description
Starpharma Holdings Limited
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Technical Analysis
Immutep Ltd
―
Dimerix Limited
―
AnteoTech Ltd
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Ownership Overview
0.83% Insiders
<0.01% Other Institutional Investors
99.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---